29:I[164923,["/_next/static/immutable/chunks/0x-9rc1bm-510.js","/_next/static/immutable/chunks/0u73ovrok9bmr.js","/_next/static/immutable/chunks/3t9ifrnugpnlb.js","/_next/static/immutable/chunks/3gdp0tzp2t65u.js","/_next/static/immutable/chunks/0qexc5596g7lf.js","/_next/static/immutable/chunks/3nkl8euu6dycn.js","/_next/static/immutable/chunks/28p3k9kvs3dfa.js","/_next/static/immutable/chunks/04j_o97cgxn2x.js","/_next/static/immutable/chunks/18bybpoq919w1.js"],"ClinicalTrialDetail"] 25:["$","script","1",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Clinical Trials\",\"item\":\"https://clareohealth.com/clinical-trials\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arterial Hypertension\",\"item\":\"https://clareohealth.com/clinical-trials/condition/arterial-hypertension\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NCT04129840\",\"item\":\"https://clareohealth.com/clinical-trials/NCT04129840\"}]}"}}] 28:T423,{"@context":"https://schema.org","@type":"MedicalWebPage","name":"Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa","description":"This study is to compare the effectiveness of three different antihypertensive treatment strategies for reaching a target blood pressure (clinic BP) of \\\u003c/= 130/80 mmHg among patients \\\u003c65years of age and \\\u003c/= 140/90 mmHg among patients \\>/=65years of Age in HIV-positive and HIV-negative patients with uncomplicated arterial hypertension in rural Tanzania and Lesotho.","url":"https://clareohealth.com/clinical-trials/NCT04129840","mainEntity":{"@id":"https://clareohealth.com/clinical-trials/NCT04129840"},"specialty":{"@type":"MedicalSpecialty","name":"Clinical Research"},"audience":{"@type":"PeopleAudience","audienceType":"Patients and Caregivers"},"lastReviewed":"2022-10-20","medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"reviewedBy":{"@type":"Organization","name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov"}}26:["$","script","2",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$28"}}] 2a:T53c,Inclusion Criteria: * HIV-positive and negative patients of African descent and black ethnicity with a documented uncomplicated, untreated arterial hypertension (blood pressure \>/=140/90 mmHg) diagnosed at one of the 2 study sites Exclusion Criteria: * Current hospitalization for any reason * Not of African descent * Refusal of an HIV-test or indeterminate HIV test result * History of cardiovascular event in the last month (anginal pain, stroke, myocardial infarction or diagnosis by a doctor) * Symptomatic arterial hypertension (blood pressure \>/=180/110 mmHg plus headache or chest pain) or acute cardiovascular event * acute disease, (e.g. fever \>37.5°C or other signs of acute concomitant infection; Dyspnea/respiratory distress; Acute pain) * Clinical signs of hypertension-mediated organ damage (heart failure, bilateral pitting edema, bilateral crackles or pleural effusion, distended jugular veins, ischemic heart disease (anginal pain on exertion), signs of current ischemic/hemorrhagic stroke (hemiparesis, loss of consciousness) * Pregnancy (test required for females 18-45years of age) * Non-consenting or inability to come for follow-up visits * creatinine clearance \/=65years of Age in HIV-positive and HIV-negative patients with uncomplicated arterial hypertension in rural Tanzania and Lesotho.","detailedDescription":null,"overallStatus":"COMPLETED","phase":"NA","studyType":"INTERVENTIONAL","conditions":["Arterial Hypertension"],"interventions":[{"type":"OTHER","name":"dual combination","description":"Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \\65years)"},{"type":"OTHER","name":"triple combination","description":"Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \\65years)"},{"type":"OTHER","name":"Standard of care","description":"Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \\65years)"}],"keywords":["antihypertensive treatment"],"locations":[{"facility":"SolidarMed Lesotho, Mokhotlong Government Hospital","city":"Mokhotlong","state":"","country":"Lesotho","zip":"$undefined","lat":-29.28939,"lng":29.06751},{"facility":"Division of Infectious Diseases & Hospital Epidemiology; University Hospital Basel","city":"Basel","state":"","country":"Switzerland","zip":"4031","lat":47.55839,"lng":7.57327},{"facility":"St. Francis Referral Hospital/ Ifakara Health Institute","city":"Ifakara","state":"Morogoro","country":"Tanzania","zip":"$undefined","lat":-8.13333,"lng":36.68333}],"eligibilityCriteria":"$2a","minAge":18,"maxAge":null,"sex":"ALL","healthyVolunteers":false,"leadSponsor":"University Hospital, Basel, Switzerland","collaborators":["Swiss National Fund for Scientific Research"],"contacts":null,"startDate":"$D2020-03-05T00:00:00.000Z","completionDate":"$D2022-09-22T00:00:00.000Z","primaryCompletionDate":"$D2022-09-22T00:00:00.000Z","firstPostDate":"$D2019-10-17T00:00:00.000Z","lastUpdatePostDate":"$D2022-10-20T00:00:00.000Z","enrollmentCount":1268,"enrollmentType":"ACTUAL","aiSummary":"$undefined","aiSummaryGeneratedAt":null,"id":"$undefined","createdAt":"$undefined","updatedAt":"$undefined"}}]

What this study is about